Webinars
Available On Demand
Whether you are an emerging, mid-tier or large-tier company preparing for launch, this webinar is a must-watch.
Join us for an informative webinar as our experts dive into Trinity Life Sciences’ latest white paper, the Trinity Annual Drug Index—an evaluation of commercial performance over three years of 58 novel drugs approved in 2020.
Hear from Blair Miller, Krista Perry, Hanson Koota and Smit Mahida from our Strategic Advisory practice as they discuss the impacts of COVID on the 2020 launch…
Watch Now
Scientific Publications
OBJECTIVES: As COVID-19 severely restricted patients’ ability to visit care settings in-person, the use of telehealth was impacted; the immediate and enduring impact on telehealth utilization is an unanswered question. This study aimed to identify medical conditions typically treated using telehealth and quantify trends in telehealth utilization through the COVID-19 pandemic.
METHODS: A retrospective analysis was performed using a 10 million-record random sample of patients with telehealth visits (with telehealth defined by CPT codes with telehealth modifiers or place-of-service codes).…
Read Now
White Papers
The Example of ASH 2021
Medical conferences are designed to bring bright minds together and pique interest and curiosity. The American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), European Society for Medical Oncology (ESMO), Gene Therapy for Rare Disorders, and other medical conferences play an important role in disseminating clinical and scientific information. Attendees range from physicians to investors, and the conferences provide a forum for peer-to-peer interactions, exposure to current research, innovative trends and an environment…
Read Now
Webinars
Available On Demand
October 28, 2021 | 1:00-1:45 pm ET
Trinity MedTech, a part of Trinity Life Sciences, invites you to our webinar, MedTech in the Post-COVID World: Where Do We Go From Here? We will share data from our real-world evidence team on key sectors within the broader MedTech industry to show the impact of COVID on different MedTech lines of business. We will also explore what the implications are moving forward for companies/brands. In particular, what are best practice companies/brands doing…
Watch Now
White Papers
The Example of ASCO 2021
While people were expecting to return to in-person conferences soon, the emergence of the Delta variant and the possibility of future unknown variants, combined with uneven vaccination rates, has created significant uncertainty about how soon that can happen. Trinity Life Sciences wanted to understand what perceptions medical conference attendees had of the new virtual conference world, what advantages and disadvantages they saw in it, and how manufacturers performed at engaging their audiences. We performed a…
Read Now
Blog
Published September 1, 2021
Executive Summary
The COVID-19 pandemic has called into question many elements of the US healthcare system across key stakeholders, resulting in changes across patients, providers, payers, researchers, and manufacturers
The pandemic has required many healthcare providers and patients to provide telemedicine options, which for many specialties has proved to be an effective way to dispense and receive care
For payers at the national level, CMS has implemented reimbursable telehealth codes for all medical services that may be provided remotely, while…
Read Now
White Papers
Despite the challenges the COVID-19 pandemic created, 2020 was an exceptional year for the biopharma industry. The race to develop effective treatments and vaccines for COVID elevated the public’s perception of biotechnology, and, for many, the industry provided a source of hope during the pandemic. As early-stage venture capitalist Bruce Booth observed in his review of 2020, investors’ enthusiasm sent biotech indexes to all-time highs, boosted the performance of IPOs and accelerated venture capital funding. The NASDAQ Biotech Index finished…
Read Now
White Papers
In this article, we aim to explain how monoclonal antibodies can help in the fight against the COVID-19 pandemic. While there are still unknowns about these drugs – such as their real-life efficacy and long-term effects, amongst others –antibodies nonetheless have the potential to effectively target several stages of the disease with evident benefits at a patient level (by alleviating symptoms and preventing progression to severe disease) and at a systemic level (by reducing the strain on the overburdened health…
Read Now
Briefs
As the year began, we couldn’t have foreseen the unprecedented impact the COVID-19 pandemic would have on US and Global enterprises. By mid-March, we were in lock-down, and priorities for Commercial and Medical Affairs organizations in the life sciences industry shifted. Leaders were working feverishly to enable virtual and digital channels to engage with customers as well as internal teams. Companies reached out to TGaS Advisors for our guidance in navigating this uncharted territory, and we stepped up to proactively…
Read Now
White Papers
What is and isn’t working for drug launches amid COVID-19? Six months after COVID-19 lock-downs began, Trinity has uncovered some surprising (and some concerning) answers to key questions everyone is asking.
In this paper, we examine the trajectory of new molecular entities (NMEs) approved in late 2019 and early 2020 to understand how to drive a successful drug launch (and avoid the pitfalls) in the age of COVID-19.
By submitting this form, creating an account, and/or using our website (or…
Read Now
